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Abstract
WISP-2 mRNA and protein was overexpressed in
preneoplastic and cancerous cells of human breast.
Statistical analyses show a significant association
between WISP-2 expression and estrogen receptor
(ER) positivity. In normal breast, the expression was
virtually undetected. The studies showed that WISP-2 is
an estrogen- induced early response gene in MCF-7
cells and the expression was continuously increased to
reach a maximum level at 24 h. The estrogen effect was
inhibited by a pure antiestrogen (ICI 182,780). Human
mammary epithelial cells, in which WISP-2 expression
was undetected or minimally detected, responded to
17B -estradiol by upregulating the WISP-2 gene after
transfection with ER-A, providing further evidences that
WISP-2 expression is mediated through ER-A. Over-
expression of WISP-2 mRNA by estrogen may be
accomplished by both transcriptional activation and
stabilization. MCF-7 cells exposed to progesterone had
a rapid but transient increase inWISP-2 expression, and
PR antagonist RU38486 blocked this mRNA induction. In
combination with estradiol, progesterone acted as an
antagonist inhibiting the expression of WISP-2 mRNA.
Moreover, disruption of WISP-2 signaling in MCF-7
cells by use of antisense oligomers caused a significant
reduction in tumor cell proliferation. The results are
consistent with the conclusion that WISP-2 expression
is a requirement for breast tumor cells proliferation.
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Introduction
Breast cancer is the most common cancer in women and the
third leading cause of cancer mortality, following lung and
stomach cancer [1–3]. The incidence rates of breast cancer
in the U.S. have more than doubled in the past three decades
[4]. The lifetime risk is 1 in 8. It is estimated that 1.2 million
new diagnoses and 500,000 deaths from breast cancer will
occur worldwide this year [5–8]. Breast cancer is the most
commonly diagnosed cancer in women in America and
worldwide. However, treatment of this disease at the ad-
vanced stages is usually ineffective. Therefore, identification
of the genes involved in the development of breast cancer is a
high priority for the medical management of the disease.
TheWnt signal transduction pathway plays a critical role in
a variety human cancers, including colon and breast, by
modulating multiple oncogenes and tumor suppressor genes
[9–12]. Alterations in Wnt signaling pathways have also
been consistently implicated in mammary gland tumo-
rigenesis in rodents [9,13,14]. The mouse mammary tumor
was potentiated by a Wnt-1 gene when it was activated by
a retroviral insertion [13,15–17]. During the transformation,
the activated Wnt-1 gene induces several down-stream
target genes including Wnt-1 induced signaling/secreted
protein-2 (WISP-2), a member of the connective tissue
growth factor /cysteine-rich 61/neuroblastoma overexpres-
sed (CCN) family of growth factors [18–20]. Although, a
similar viral etiology or Wnt-1 expression has yet to be
established for breast cancer in humans [13], our recent
studies have demonstrated that the WISP-2 expression,
undetected in non–transformed human mammary epithelial
cells (HMEC), was upregulated in different human mammary
tumor cell lines [21], and its expression was modulated by
serum and correlated with the serum- induced tumor cell
proliferation [22]. Collectively, these studies suggest that
WISP-2 could be an important growth factor for development
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of breast cancer and more importantly a genetic marker for
this disease [21].
To directly test the hypothesis that the WISP-2 is an
important growth factor for the development of this disease
and could be considered as genetic marker, we determined
the WISP-2 expression at mRNA and protein levels in the
biopsy samples of breast tumors with different variables. In
addition, the impact of this gene on breast tumor cell
proliferation was evaluated by blocking its activities and the




Dulbecco’s modified Eagle’s medium (DMEM) was pur-
chased from Sigma Chemical (St. Louis, MO), FBS was
purchased from American Type Culture Collection (Mana-
ssas, VA), and reverse transcription-polymerase chain
reaction (RT-PCR) kits were purchased from Perkin-Elmer
(Foster City, CA). Biolase DNA polymerase was purchased
from Bioline USA (Nevada, USA). Digoxigenin (DIG) high
prime DNA labeling and detection kit (Cat nos. 1636090 and
1585614) was obtained from Roche Diagnostics GmbH
(Indianapolis, IN). Estrogen receptor a (ER-a ), progester-
one receptor (PR), and P53 monoclonal and polyclonal
antibodies were purchased from Lab Vision (Fremont, CA)
and Santa Cruz Biotechnology (Santa Cruz, CA). A custom-
made WISP-2 polyclonal antibody [22] was used for this
study. Antiestrogen ( ICI 182,780) and antiprogesterone
(RU38486) were purchased from Tocris (Ellsville, MO). All
other chemicals from commercial sources were of the
highest purity available.
Tissue Samples
Frozen specimens including normal human breast tissues,
non–neoplastic breast tissues and primary breast carcino-
mas were obtained from the Kansas Cancer Institute Tissue
Repository Core facilities and Cooperative Human Tissue
Network (CHTN, NCI), respectively. Twenty normal frozen
tissue specimens were obtained from healthy women,
undergoing surgery for breast reduction at the University of
Kansas Medical Center. Twenty- four non–neoplastic speci-
mens, confirmed by histopathological examination, were
isolated from adjacent invasive carcinoma. Fifty- four primary
breast carcinoma specimens included 10 pure invasive
carcinoma and 44 invasive carcinomas mixed with preneo-
plastic lesions ( i.e., simple hyperplasia, atypical hyperplasia,
and intraductal carcinoma in situ (DCIS) ] were analyzed. For
H&E stain and immunohistochemistry, part of the frozen
specimens were fixed in 4% formalin and embedded in
paraffin. The categorization of simple hyperplasia, atypical
hyperplasia, ductal carcinoma in situ, and ductal carcinoma
was based on the primary pathological diagnosis.
Cell Lines and Culture Conditions
The MCF-7 human breast carcinoma cell line and non–
transformed HMECwere used for these studies. The MCF-7
cells were obtained from American Type Tissue Culture Col-
lection (Rockville, MD) and maintained in DMEM (Sigma)
containing 10% FBS. ER-a - or vector only- transfected
HMEC were a gift from Deborah Zajchowski (Berlex Bio-
sciences, CA) and grown in DFCI-1 mediumwith 1% FBS as
previously described [23,24].
Immunohistochemistry
Immunohistochemical analysis was performed according
to our previous method [25]. Tissues sections were depara-
ffinized, blocked with tissue blocker (Zymed Laboratories,
CA) for 10 min and immunostained by using Zymed broad
range immunohistochemical kits with overnight incubation
with the WISP-2 antibodies.
RNA Extraction, cDNA Synthesis, PCR Amplification, and
Probe Preparation
Cytoplasmic RNA was extracted from breast tissue
specimens and different cell lines using the Trizol (Life
Technologies, Grand Island, NY) extraction procedure, as
previously described [22].
For cDNA preparation, 1 g of total RNA from each
sample was subjected to reverse transcription using a
Perkin-Elmer RT-PCR RNA amplification kit in a total
reaction volume of 20 l. The reverse transcription product
was diluted to 50 l, and 2 l of this diluted product was PCR
amplified in a 50-l reaction mixture containing 0.5 M of
each appropriate oligonucleotide primer, 200 M dNTP, and
1.5 U of Biolase DNA polymerase. The PCR profiles for
WISP-2 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were the same as previously described. The PCR
products were separated by electrophoresis through 3%
NuSieve 3:1 agarose gel followed by ethidium bromide
staining and visualized by UV fluorescence. For each
analysis, a negative control was prepared using all reagents
except MuLV and 1 l of the matching RNA yielded no
detectable products, indicating that all RNAs were free of
DNA contamination. The efficiency of cDNA synthesis from
each sample was estimated by coamplification of GAPDH
gene with specific primers. The sequences of primers are
as follow: WISP-2 (GenBank accession number: XM
0095188): 50 -CCT ACA CAC ACA GCC TAT ATC (nts.
1042 to 1063; Forward) and 50 -CCT TCT CTT CAT CCT
ACC C-30 (nts. 1177 to 1196; Reverse), and GA3PDH
(GenBank accession number: AF 261085): 50 -ATG AGA
AGT ATG ACA ACA GCC-30 (nts. 513 to 533; Forward) and
50 -TGA GTC CTT CCA CGA TAC C-30 (nts. 608 to 626;
Reverse). A low DNA mass ladder DNA molecular weight
marker was used to determine the size of the test reaction.
To prepare the DIG- labeled nonradioactive probes for
WISP-2 and GAPDH, 10 l cDNA, prepared from total RNA
of MCF-7 cells, was PCR amplified according to the
manufacturer’s instructions (PCR DIG probe synthesis kit,
Roche Applied Science) in the presence of DIG- labeled
dNTP mixture and WISP-2 or GAPDH specific primers.
In Situ Hybridization
In situ hybridization was performed essentially as
described by the manufacturer ( Innogenex, San Ramon,
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CA) with minor modifications. Five-micrometer paraffin sec-
tions were deparaffinized with xylene, hydrated in ethanol /
water solutions and digested with proteinase K (ready to use
vial ) for 10 min followed by postfixation in 1% formaldehyde/
1 PBS for 10 min at room temperature. The slides were
washed with RNAse- free distilled water for 5 min. The DIG-
labeled PCR generated WISP-2 probes were added to a
slide at concentration of 250 ng/ml hybridization buffer (100
l /section) and incubated overnight at 378C in a humidified
in situ hybridization chamber. Sections were washed with
2 PBS with 0.1% Tween-20 for 10 min and the following
sequence with 3 min per step: 1 PBS, 0.1% Tween-20,
0.5 PBS and 0.2 PBS. The hybridized DIG- labeled probe
was detected using alkaline phosphatase-conjugated anti–
DIG antibody ( Innogenex) and visualized with chromogen
combination 5-bromo-4-chloro-3- indolyl phosphate and
NBT. The sections were counterstained with nuclear first red.
Northern Blot Analysis
For Northern blot analysis, 10 g of total RNA was frac-
tionated by electrophoresis in 1.0% agarose gels containing
formaldehyde and transferred to super charge nylon mem-
brane (Schleicher & Schuell, Keene, NH). Membranes were
hybridized with nonradioactive RT-PCR generated-DIG-
labeledWISP-2 orGAPDH gene specific probe and washed
according to the protocols provided by the manufacturer of
the DIG high prime DNA labeling and detection kit.
Relative expressions of WISP-2 mRNAs were calculated
by densitometric analyses using the Gelexpert software
program (NeucleoTech, CA). The signal intensity of WISP-2
bands was normalized to that obtained with the GA3PDH
bands.
Western Immunoblot Analysis
Cell extracts were prepared for immunoblotting according
to our previous method [26]. Briefly, cells were lysed in 1 ml
of RIPA buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1%
Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl
sulfate) containing 1 mM sodium orthovanadate, for phos-
phatase inhibition, 0.5 mM phenylmethylsulfonyl fluoride,
1 M/ml leupeptin, 1 M/ml aprotinin, and allowed to in-
cubate on ice for 10 min. The lysate was cleared by
centrifugation at 15,000 rpm for 60 min at 48C and the
supernatants were collected and frozen at 708C.
Cell lysates corresponding to 50 g protein [determined
using Coomassie blue reagent assay (Bio-Rad, Richmond,
CA) ] were subjected to 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and the gel - fractionated
proteins transferred to nitrocellulose membranes (Bio-Rad)
for the detection of WISP-2 protein. A custom-made poly-
clonal WISP-2 antibody [22] was used as primary antibody
for this assay.
WISP-2 Antisense Assays
Antisense (AS) and mismatch WISP-2 second gener-
ation chimeras (50 -7 phosphorothioates, 11 20 -O -methyl
RNA, 1 sulfur linkage and inverted T) oligonucleotides were
designed using a computer program (Vector NTI Suite,
InforMax), synthesized and obtained from Oligos Etc. (Oligo
Therapeutics Inc., Wilsonville, OR). The purity of the oligos
was confirmed by polyacrylamide gel electrophoresis. The
sequences of AS oligos were: WISP-2 AS1, 50 -CTT CGG
TGT GCC TCT CAT-30 (coding region), WISP-2 AS2, 50 -
ATGGTC AAC TAA ATCGTC-30 (untranslated region), and
mismatch oligos, 50 -CTG CTA AAT CCA CTG TGA-30. The
mismatched oligos were used as a control.
For determining the effects of antisense oligonucleotides
on WISP-2 expression and upon serum- induced cellular
proliferation, MCF-7 cells were treated with different
oligonucleotides. The treatment of oligos was performed by
a previously described method with somemodifications [27–
29], Briefly, semiconfluent MCF-7 cells were trypsinized and
resuspended in DMEM containing 10% FBS and were
seeded in 96-well plates (Coster, Cambridge, MA) at the
density of 2500 cells /well. After 48 h of culture, to minimize
the endogenous WISP-2 protein levels and its signals
stimulated by serum, cells were washed once with serum-
free Opti -MEM medium (Life Technologies) and grown in
the same medium for 72 h. After 72 h, cells were treated with
various concentrations of antisense oligos dissolved in 7.5
M lipofectamine (Life Technologies) for 24 h, washed and
refed with DMEM containing 10% FBS. In this study, two sets
of controls were used: 1) Cells unexposed to oligos were
exposed to the 7.5-M lipofectin to ensure lack of an effect
from the reagent. These cells were considered the lipofectin
control; 2) Negative controls consisted of cells that were
exposed to neither oligos nor lipofectin.
To determine the effects of antisense oligonucleotides on
serum- induced WISP-2 protein synthesis, MCF-7 cells
(1105/plate) were plated in six -well plates and allowed to
grow for 48 h. After 48 h, the cells were grown in serum-free
Opti -MEM medium for 72 h followed by incubation with 500
or 1000 nM AS1 WISP-2 antisense or 500 nM mismatch
oligomers for 24 h. After this time, cells were washed and
refed with DMEM containing 10% FBS. The culture was then
continued for an additional day. The expression of WISP-2
protein in various cultures was evaluated by Western blot
analysis. Each experiment was performed in triplicate.
[ 3H] -Thymidine Incorporation Assay
The radioactive thymidine incorporation assay was the
same as previously described [30]. Briefly, cells treated with
oligonucleotides or untreated, were pulsed for 6 h of final
culture with 0.25 Ci [3H]- thymidine/well (NEN Research,
Wilmington, DE). Then, the cells were precipitated with 10%
trichloroacetic acid, filtered through glass fiber filters and
dried. The amount of incorporated tritium was measured
using a liquid scintillation counter (Beckman Instruments,
Fullerton, CA).
Statistical Analysis
For the statistical analysis of association with variables
and WISP-2 expression in breast cancer samples, the
variables were divided into two groups, which are catego-
rical variables and quantitative variables. Categorical vari-
ables including ER, PR, p53 immunolabeling status, and
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grades were summarized by frequencies and percentages
and quantitative variables, which included size of tumor,
age, and lymph node metastasis, then summarized by
median and range. Chi -square and Fisher’s exact tests
were utilized to determine an association of categorical
variables with WISP status. The Wilcoxon rank sum test was
used to determine if differed quantitative variables differed
between WISP-2 positive or negative. Northern blot data
are presented as mean±SE and analyzed by using either
Student’s t test. A type I error rate of 5% was used for all
tests and an associated probability (P value) of <0.05 was
considered significant.
Results
WISP-2 mRNA Levels and Cellular Localization of WISP-2
mRNA and Protein in Normal, Non–Neoplastic and
Neoplastic Human Breast
The expression of WISP-2 mRNA was first confirmed
in different breast samples using RT-PCR analysis with
WISP-2 specific primers (Figure 1). The histologic distri-
bution of WISP-2 mRNA and protein was localized in
formalin- fixed, paraffin -embedded tissue sections using
nonradioactive in situ hybridization and immunohistochem-
istry (Figure 2). A total of 98 breast samples, histologically
classified according to the standard criteria [31,32], were
used for these studies. These included 20 normal, 24 non–
neoplastic, and 54 invasive ductal carcinoma specimens with
or without preneoplastic lesions. For cellular localization of
WISP-2 mRNA or protein, tissue samples were analyzed
simultaneously in a multitissue format to avoid potential
immunostaining artifacts including slide- to-slide and run-
to- run variability.
Normal and non–neoplastic tissue samples In normal
breast tissue, expression ofWISP-2mRNA was undetected
or minimally detected by RT-PCR and in situ hybridization
analyses as represented in Figures 1 and 2A, respectively.
WISP-2 mRNA expression correlated well with their
respective protein levels in the same adjacent tissues as
determined by immunohistochemical labeling with WISP-2
antibodies (Figure 2B ).
In non–neoplastic specimen, as was present in most of
the tumor samples, WISP-2 mRNA expression was identi-
fied in about 46% (11 of 24) samples (Figure 1), whereas
WISP-2 protein was detected in about 62% (15 of 24)
samples by immunohistochemical labeling using antibodies
to WISP-2 and proteins were mainly confined in the
epithelial cells of the ducts and lobules. However, staining
intensity for both mRNA and protein varies from weak to
strong in this sample. Strong staining was found in three
non–neoplastic samples.
Figure 1. RT-PCR analyses of WISP-2 mRNA expression in normal and
tumor samples of human breast. Lanes 1–4, the representative biopsy
samples of human breast tumor; Lanes 5 and 7, the representative biopsy
samples of non–neoplastic breast adjacent to the tumors; Lanes 6 and 8,
the representative biopsy samples of normal breast. Lane M, DNA markers.
The representative RT -PCR of GAPDH mRNA exhibiting the quality of
RNA. The predictive PCR-product size of WISP-2 is 155 bp and that of
GAPDH is 114 bp.
Figure 2. Representative nonradioactive in situ hybridization and immuno-
histochemical photomicrographs exhibiting the distribution of WISP -2 mRNA
(blue ) andWISP -2 protein ( brown ) in ductal epithelial cells and tumor cells in
human breast. (A and B) Ducts and lobules of normal breast; original
magnification, 400. (C and D) Benign duct adjacent to the tumor; original
magnification, 400. (E and F ) Ductal carcinoma in situ; original magnifica-
tion, 400. (G and H) Invasive ductal carcinoma; original magnification,
400.
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Invasive carcinoma samples To determine the WISP-2
mRNA and protein status in invasive ductal carcinoma in
breast as well as the association of this expression with other
pathophysiological changes, 54 samples with pathological
variables (Table 1) were studied. WISP-2 mRNA and
protein expression were detected in 68.5% (37 of 54) breast
tumor samples (Table 1). The level of expression was signi-
ficantly higher in breast tumor samples when compared to
normal or non–neoplastic breast samples (Figure 1). The
WISP-2 mRNA and protein was mainly identified in the epi-
thelial cells and tumor cells. The immunostaining with the
WISP-2 antibody was predominantly cytoplasmic (Figure 2).
Notably strong WISP-2 mRNA and protein expression were
detected in the preneoplastic lesions ( i.e., DCIS) that
coexisted with invasive cancers (Figure 2, E and F ).
The statistical analyses comparing categorical variables
between WISP-2-positive and WISP-2-negative breast
cancer samples showed that 20 of 37 (54%) of the positive
specimens were ER-a -positive and 14 of 17 (82.4%) of the
negative specimens were ER-a -negative. This suggests a
significant association (P=0.0174) between WISP-2 and
ER-a (Table 2). Actually, WISP-2 positivity increases the
odds of being ER-positive by 5.5. There were no associa-
tions between WISP-2 expression and other categorical
variables such as PR or p53 status and grades (Table 2).
The comparison of quantitative variables between WISP-
2-positive and WISP-2-negative specimens showed that
WISP-2 expression was independent of size, age, and LN
status (Table 3). There were no significant statistical
differences in the incidence of WISP-2 expression when
compared with the grades (P<.3676), size (P<.5663), age
(P<.7798), and LN (P<.1072).
Table 1. Pathological Information of the Human Female Breast Ductal
Carcinoma Samples.
Case no. Age Size LN* Grade ER-a PR p53 WISP-2
expressiony
1 65 T2 3 I + + + +
2 34 T1 1 III +  + +
3 39 T2 2 II  + + 
4 38 T2 2 II + + + +
5 67 T3 2 I +  + +
6 50 T2 0 II +  + 
7 37 T2 10 III   + 
8 52 T2 14 II +  + +
9 84 T3 0 II   + +
10 40 T2 0 III   + 
11 64 T2 0 III   + +
12 61 T4 0 II +  + +
13 35 T1 0 II   + +
14 66 T2 0 II   + +
15 58 T3 4 I   + +
16 49 T3 5 III    
17 75 T1 0 II + + + 
18 44 T2 1 I + + + +
19 40 T2 0 III   + 
20 49 T2 2 III   + 
21 50 T2 0 I  + + 
22 71 T3 3 III   + +
23 50 T3 25 II   + 
24 42 T3 4 III   + 
25 64 T1 5 I + + + +
26 32 T3 28 II    
27 60 T2 0 II   + +
28 53 T2 32 I +   +
29 73 T2 0 II   + +
30 50 T3 5 II   + +
31 46 T3 4 II   + +
32 51 T2 0 II   + +
33 59 T1 0 II +  + +
34 36 T2 0 II +  + +
35 53 T3 31 II   + 
36 69 T2 0 II   + +
37 34 T2 6 I   + +
38 36 T3 6 III + +  +
39 60 T3 6 II   + 
40 49 T3 12 II + + + +
41 48 T3 0 III +  + +
42 36 T2 0 III    +
43 34 T1 0 I +  + +
44 54 T3 0 I + + + +
45 41 T1 0 II + + + +
46 67 T2 4 II +   
47 43 T1 0 II + +  +
48 31 T2 1 II   + +
49 41 T3 0 III   + +
50 42 T1 0 I + + + +
51 55 T2 5 II   + 
52 59 T1 0 I    
53 52 z 0 II + +  +
54 54 T1 1 II +   +
*LN: axillary lymph node metastasis.
ymRNA and protein expressions were determined using in situ hybridization
and immunohistochemistry.
zThe tumor was multifocal involving many foci throughout the biopsy;
therefore, tumor size cannot be evaluated.
Table 2. Comparison of Categorical Variables between WISP -2 -Positive
and WISP -2 -Negative Breast Cancer Samples.
Variable* WISP -2+ n (% ) WISP -2n (% ) P value
ER-a
Positive 20 (54.0 ) 3 (17.7 ) 0.0174
Negative 17 (46.0 ) 14 ( 82.3 )
PR
Positive 11 (29.7 ) 3 (17.7 ) 0.5073
Negative 26 (70.3 ) 14 ( 82.3 )
p53
Positive 31 (83.8 ) 13 ( 76.5 ) 0.7075
Negative 6 (16.2 ) 4 (23.5 )
Gradey
1 10 (27.0 ) 2 (11.8 ) 0.3676
2 19 (51.4 ) 9 (52.9 )
3 8 (21.6 ) 6 (35.3 )
n, number of breast cancer samples.
*WISP-2 data were collected from in situ hybridization and immunohisto-
chemical analyses; ER, PR, and p53 data were collected from immunohis-
tochemical analyses.
y1, well differentiated; 2, moderately differentiated; and 3, poorly differentiated.
Table 3. Comparison of Quantitative Variables between WISP -2 -Positive
and WISP -2 -Negative Breast Cancer Samples.
Variable WISP+Median ( range ) WISPMedian ( range ) P value
Size 2 (1–4 ) 2 ( 1–3 ) 0.5663
LN 0 (0–32 ) 4 ( 0–31 ) 0.1072
Age* 51 (31–84 ) 50 (32–75 ) 0.7798
*Age (year ) at the diagnosis of the breast cancer.
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Time- and Dose-Dependent Effects of Estradiol on WISP-2
mRNA Expression in MCF-7 Breast Tumor Cells
Previous studies, by our laboratory and others, have
shown thatWISP-2mRNA expression was upregulated by a
natural estrogen, 17b -estradiol (17b -E2), in MCF-7 breast
tumor cells [33,34]. In the present studies, time- and dose-
dependent effects of estrogen onWISP-2mRNA expression
were evaluated. For this experiment, MCF-7 cells were
Figure 3. Effects of estrogen and progesterone onWISP -2 mRNA expression in a MCF-7 cell line. (A, C, and E ) Exponentially growing MCF-7 ER+ breast cancer
cells in phenol - red - free DMEM containing 10% FBS were serum starved for 3 days before exposure to 17b -E2 ( 110 8 M ) or P4 (110 8 M) or in combination
for different times. The total RNA was extracted from cells harvested at indicated times and analyzed by Northern blotting using nonradioactive DIG - labeled PCR
generated probes for WISP-2 and GAPDH. (B, D, and F ) The arbitrary values indicate WISP-2 mRNA concentrations. Data displayed as mean±SD from three
separate experiments. P value was determined by Student’s t test. *P< .01 versus control; **P< .005 versus control; ***P< .0001 versus control.
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grown in phenol red- free and serum-free medium for 3 days
to make the complete estrogen- free environment and mini-
mize theWISP-2 expression levels. After 3 days, cells were
exposed for various lengths of time to 17b -E2 (1108 M),
and WISP-2 mRNA levels were determined by nonradioac-
tive Northern blot analysis. As shown in Figure 3, WISP-2
mRNA expression was induced by 2.5- fold as compared to
untreated control after 30 min of 17b -E2 exposure and it
steadily increased by 9.9- fold until 24 h (Figure 3, A and B ).
The levels were slightly reduced after 48 h of exposure (data
not shown). Because at 24 h of 17b -E2 (1108 M)
exposure exhibits maximum induction of WISP-2 mRNA,
next we determined the impact of different doses of 17b -E2
( i.e., 1109, 11010, and 11011 M) on WISP-2
mRNA expression in MCF-7 cells for identical time frame.
The upregulation of WISP-2 mRNA levels by 17b -E2 was
first detected at 11011 M concentration, which was 2.8-
fold higher than untreated controls (Figure 4, A and B ). The
expression levels were improved correspondingly as the
dose of estradiol increased (Figure 4, A and B ). No impact
was perceived when cells were exposed to 11012 M or
less concentration of 17b -E2 (data not shown). Collectively,
these findings show that estrogen transiently and steadily
induced WISP-2 mRNA expression and this upregulation is
dose dependent in MCF-7 breast tumor cells.
Estradiol - Induced Upregulation of WISP-2 mRNA
Expression in Tumor Cells is ER-a Mediated
To determine whether estrogen- induced upregulation of
WISP-2 mRNA expression is mediated through ER, first the
impact of 17b -E2, and a pure antagonist of ER ICI 182,780
on estrogen-responsive human breast tumor derived MCF-
7 tumor cells was explored. Cells were exposed 17b -E2
(1108 M) alone or in combination with ICI 182,780
(1106 M) for 24 h, and then WISP-2 mRNA levels were
evaluated by Northern blot analysis using nonradioactive
DIG- labeled PCR generated probe. As shown above, 17b -
E2 alone increasedWISP-2 mRNA levels in MCF-7 cells by
eight- fold or more as compared to untreated control (Figure
5, A and B ). Whereas cells were exposed to 17b -E2 along
with ICI 182,780, estrogen- induced upregulation of WISP-2
expression was inhibited significantly (Figure 5B ). Taken
together, studies indicate that the induction was mediated
through ER. To confirm this conclusion, non–transformed
and estrogen-non–responsive HMEC with or without stably
transfected with ER-awere grown in serum-free medium for
3 days and then exposed to 17b -E2 (1108 M) for 2 and 24
h. WISP-2 mRNA levels were increased significantly in ER-
a - transfected HMEC by 6.7- and 4.9- fold after 2 and 24 h of
17b -E2 exposure, respectively, as compared to untreated
cells (Figure 6, A and B ). However, unlike tumor cells, the
level of expression was significantly higher at 2 h as
compared to 24 h (Figure 6, A and B ). The estrogenic effect
on WISP-2 mRNA expression was undetected in HMEC
transfected with vector only (Figure 6, C and D ). This study
supports the previous data (Figure 5) and indicates that ER-
a is required to mediate the 17b -E2 action on WISP-2
mRNA expression.
Effects of Estradiol on WISP-2 mRNA Transcription and
Stability in MCF-7 Breast Tumor Cells
Because 17b -E2 steadily upregulated WISP-2 mRNA
expression for 24 h, we determined whether this was at the
level of transcription or increased stability of mRNA in the
tumor cells. MCF-7 cells were left untreated or exposed to
17b -E2 (1108 M) for 2 h before the addition of the RNA
Figure 4. Dose -dependent effects of estrogen and progesterone on WISP -2
mRNA expression in MCF-7 cells. (A and C) Exponentially growing MCF-7
ER+ breast cancer cells in phenol - red - free DMEM containing 10% FBS were
serum starved for 3 days before exposure to different doses of 17b -E2 and P4
for 24 and 1 h, respectively. Total RNA was extracted and analyzed by RNA
blotting using nonradioactive DIG - labeled PCR generated probes for
WISP-2 and GAPDH. ( B and D ) The arbitrary values indicate WISP-2
mRNA concentrations. Data displayed as mean±SD from three separate
experiments. P value was determined by Student’s t test. *P< .001 versus
control; **P< .01 versus control.
Figure 5. Effects of pure antiestrogen ICI 182,780 and antiprogesterone
RU38486 on estrogen and progesterone - induced WISP -2 mRNA expres-
sion. (A and C ) Serum starved MCF-7 ER+ breast cancer cells were
exposed to either 110 8 M 17b -E2 in the absence ( control ) or presence of
ICI 182,780 (110 6 M) for 24 h or 110 8 M P4 alone or in combination
with RU38486 (110 6 M) for 1 h. Total RNA was extracted and analyzed
by RNA blotting using nonradioactive DIG - labeled PCR generated probes
for WISP-2 and GAPDH. ( B and D) The arbitrary values indicate WISP-2
mRNA concentrations. Data displayed as mean±SD from three separate
experiments.
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synthesis inhibitor, actinomycin-D (3 g/ml). As shown in
Figure 7, 17b -E2 treatment showed a marked induction of
WISP-2 mRNA partially abrogated in the presence of
actinomycin-D. On the contrary, actinomycin-D had no
impact on WISP-2 mRNA expression in estrogen-untreated
cells (Figure 7). Longer exposure (24 h or more) of
actinomycin-D abolishes the constitutive (untreated) and
estrogen- induced WISP-2 mRNA expression (data not
included), which is in agreement with previous work [33].
These results conclude that estrogen may regulate the
WISP-2 gene at the transcription level as well as by
increased stability of WISP-2 mRNA.
Modulation of WISP-2 mRNA Expression by Progesterone
in MCF-7 Breast Tumor Cells
To determine the impact of progesterone (P4) onWISP-2
mRNA expression, MCF-7 cells were grown in a serum-free
environment for 3 days, and then cells were either exposed
to P4 (1108 M) for different times or different doses of P4
for single time point that has been selected from the result of
different time-dependent effect studies. WISP-2 mRNA
expression was significantly elevated after 30 min of P4
exposure and reached maximum levels at 1 h (Figure 3, C
and D ). The basal level of expression was obtained at 4 h, or
longer, exposure. Moreover, WISP-2 mRNA level was
increased in MCF-7 cells by nanomolar dose of P4 (Figure
4, C and D ). The impact was undetected at picomolar levels.
To determine if progesterone receptor (PR) can mediate
rapid induction of WISP-2 mRNA by P4 in MCF-7 cells, we
tested the ability of the progesterone receptor antagonist
RU38486 (mifepristone) to block P4- induced upregulation of
WISP-2 mRNA expression. As shown in Figure 5, C and D,
RU38486 (1 M) significantly inhibited the increase in
WISP-2 mRNA expression by P4 in MCF-7 cells. These
data together with the above studies indicate that transiently,
upregulation of WISP-2 expression by P4 can be mediated
through a progesterone receptor.
P4 usually antagonizes estrogen action and inhibit estro-
gen- induced cell proliferation as well as the growth of
estrogen-dependent cancer [35,36]. Therefore, the effect of
P4 on 17b -E2- induced WISP-2 upregulation was deter-
mined. P4 exhibited an antagonizing effect on WISP-2
mRNA expression in the presence of 17b -E2 and also
inhibited 17b -E2- induced WISP-2 expression as shown in
Figure 3, E and F.
Effect of WISP-2 Antisense Oligos on Serum-Induced
Tumor Cell Proliferation and WISP-2 Protein Synthesis
To determine the functional role of WISP-2 on tumor cell
proliferation, the impact of two different WISP-2 antisense
oligonucleotides on MCF-7 cell proliferation was examined.
Cells were treated with various concentrations (100, 200,
and 500 nM or 1 M), of antisense oligos and cellular
proliferation determined using [3H]- thymidine incorporation
assays. The results obtained at 24 h after antisense
treatments are depicted in Figure 8. The degree of impact
of two different antisenses on MCF-7 cell proliferation was
not identical. The antisense oligos AS1 (50 -CTT CGG TGT
GCC TCT CAT-3) exhibited a higher inhibitory effect at a
dose of 500 nM, or higher, as compared to AS2. At a
concentration of 500 nM, AS1 oligos inhibited the [3H]-
thymidine incorporation by 77%, whereas no significant
inhibition was observed at 100 nM. Cells treated with 7.5 M
Figure 6. Effects of estrogen on ER -a - transfected and non– transfected
normal human mammary epithelial cells. (A ) Serum-starved ER- transfected
or (C ) only vector - transfected cells were exposed to 110 8M 17b-estradiol
for 2 or 24 h. Total RNA was extracted and analyzed by RNA blotting using
nonradioactive DIG - labeled PCR generated probes for WISP -2 and
GAPDH. ( B and D) The arbitrary values indicate WISP-2 mRNA concen-
trations. Data displayed as mean±SD from three separate experiments.
P value was determined by Student’s t test. *P< .001 versus control; **P< .004
versus control.
Figure 7. Effects of estrogen on mRNA stability and transcriptional activation
of WISP -2 gene in MCF-7 cells. (A ) Exponentially growing MCF-7 ER+
breast cancer cells were serum starved for 3 days, and then exposed to 17b -
E2 ( 110 8 M) or vehicle ( ethanol ) alone for 2 h before actinomycin -D (3
g /ml ) was added into the media for 2 h. Total RNA was extracted and
assessed for nonradioactive Northern blotting analysis using DIG - labeled
PCR generated probes for WISP-2 and GAPDH. (B ) The arbitrary values
indicate WISP-2 mRNA concentrations. Data displayed as mean±SD from
three separate experiments. P value was determined by Student’s t test.
*P< .01 versus control; **P< .005 versus control; p, P< .05 versus actino-
mycin -D treated.
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lipofectamine alone or exposed to mismatch oligos at various
concentrations ranging from 100 nM to 1 M underwent
logarithmic cell growth (Figure 8A ). The inhibitory effects of
WISP-2 AS1 oligos on MCF-7 cells were further confirmed
using BrdU-ELISA assays, in which BrdU incorporation was
consistently and significantly reduced when cells were
exposed to 500 nM AS-1 oligos as compared to unexposed
cells (data not shown). Lipofectamine and mismatch oligos
exhibit no significant changes in radioactive thymidine
incorporation.
To validate that the AS1-antisense- induced inhibition of
cell proliferation was mediated through inhibition of protein
expression in MCF-7 cells, WISP-2 protein synthesis was
evaluated using Western blot analysis. Preincubation of cells
for 24 h with 500 or 1000 nM AS1 antisense oligos sig-
nificantly reduced the impact of serum on WISP-2 protein
synthesis when compared to the cells treated with nonsense
oligomers (Figure 8B ). The relative intensity of WISP-2
protein after 500 nM AS1 antisense treatment was 2.8- fold
less after serum stimulation.
Discussion
WISP-2 is Overexpressed in Preneoplastic and Neoplastic
Breast Diseases and is Correlated with ER Positivity
Our recent data have shown by differential display and
RT-PCR analyses that WISP-2 mRNA was overexpressed
in different breast tumor cell lines such as MCF-7, ZR-75,
SKBR-3, and T-47D, but the expression was virtually
undetected in normal mammary epithelial cells (HMEC)
[21]. Further studies have demonstrated that WISP-2 is a
serum- induced early response gene, and cellular content of
mRNA and protein was maximal during the process of
serum- induced tumor cell proliferation [22]. Moreover,
these studies implied a major role for WISP-2 signaling in
tumor cell proliferation [22]. The findings presented in this
study demonstrated that WISP-2 was expressed in 68%
ductal carcinoma tissue samples (Table 1) and undetectable
or barely detectable in normal breast tissue samples as
shown by RT-PCR, in situ hybridization, and immunohis-
tochemical analyses (Figures 1 and 2). The WISP-2 was
also detected in preneoplastic lesions [ i.e. atypical ductal
hyperplasia (ADH) and DCIS] in tumor samples. WISP-2
protein was primarily localized in the cytoplasm of ductal
epithelial cells or tumor cells, and was undetected in stromal
cells and blood vessels by conventional in situ hybridization
and immunohistochemical analyses. Moreover, the statis-
tical evaluations indicate that WISP-2 expression was
frequently associated with ER positivity. No statistical
correlation was found with other variability including age,
size, and grade of the tumors, LN, PR, or P53 status. Taken
together, the studies suggest that WISP-2 expression may
be an early genetic lesion that is closely associated with the
development of breast cancer. Thus, WISP-2 may serve as
a possible marker of the potential progression of the breast
cancers, which are often ER-positive.
Regulation by Sex Steroids of WISP-2 mRNA Expression
The present in vivo studies, which demonstrate a close
association between WISP-2 expression and ER positivity,
and previous studies from our lab and others have suggested
the possible role of estrogen in regulation of the WISP-2
gene [22,33,34]. In the present studies, therefore, the impact
of estrogen was evaluated more precisely. The results
Figure 8. Effects of antisense oligos treatment on the serum- induced [ 3H ] -
thymidine incorporation and WISP -2 protein synthesis in MCF-7 cells. (A )
Semi - confluent MCF-7 cells were seeded in 96 -well plates at the density of
2500 cells /well. After 48 h of culture, cells were washed one time with serum-
free Opti -MEM medium and grown in the same medium for 72 h. After 72 h,
cells were treated with indicated concentrations of antisense oligos dissolved
in 7.5 M lipofectamine for 24 h. After this time, cells were washed and refed
with DMEM containing 10% FBS. The culture was continued for one additional
day. Cells were assayed for [ 3H ] - thymidine incorporation. In this experiment,
two sets of controls were used. Results are displayed as mean±SD from three
separate experiments performed in triplicate. *P< .02 versus control; **P< .05.
(B ) MCF -7 cells ( 1105 / plate ) were plated in six -well plates and allowed
them to grow for 48 h, and then cells were grown in serum- free Opti -MEM
medium for 72 h followed by incubation with 500 or 1000 nM AS1 WISP -2
antisense or 500 nM mismatch oligomers for 24 h. After this time, cells were
washed and refed with DMEM containing 10% FBS for 24 h. The expression of
WISP -2 protein was evaluated by Western blot analysis in the lysates
obtained from cells grown in serum- free medium (Lane 1 ), cells treated with
mismatch oligomers before serum addition (Lane 2 ), cells treated with 500 nM
AS1 antisense before serum addition (Lane 3 ), and cells treated with 1000 nM
AS1 antisense before serum addition. The intensity of the bands was
quantitated using NucleoVision image analysis system and arbitrary values
indicate WISP -2 concentration in different samples. Results are displayed as
mean±SD from three separate experiments.
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presented herein indicate that natural estrogen, 17b -E2,
rapidly induces WISP-2 mRNA expression in MCF-7 breast
tumor cell line as well as in ER-a - transfected non–trans-
formed mammary epithelial cells. The mRNA expression
was progressively increased, and the effect of estrogen on
WISP-2 activation lasted for >24 h or more. Both physio-
logical and supraphysiological doses of estrogen increase
WISP-2 mRNA expression in MCF-7 cells. The inhibition of
this action of estrogen by a pure anti–estrogen ICI 182,780
indicated that the effect was mediated through the action of
ER-a. Moreover, partial inhibition of estrogen- induced
WISP-2 mRNA expression by actinomycin-D suggested
multiple actions of estrogen on WISP-2. It may regulate at
the transcription level as well as potentiates the stabilization
of WISP-2 mRNA. Further studies are warranted to confirm
these findings.
Despite controversy, it is well accepted that progesterone
(P4) is required for normal mammary gland development
and also plays a critical role in regulation of breast cancer
growth and progression [37,38]. P4 has both proliferative
and antiproliferative effects on breast epithelial cells and
cancerous breast cells [37–40]. Additionally, antagonistic
actions of progesterone on estrogen effects in normal and
breast cancer cells have been well documented [37]. This
distinctive feature of P4 persuaded us to evaluate its impact
onWISP-2 expression in the presence or absence of natural
estrogen 17b -E2. The studies indicated a dual action of pro-
gesterone. Alone, P4, with different doses, rapidly upregu-
lated WISP-2 mRNA expression in MCF-7 cells, but unlike
that of estrogen, this action was transient and decreased
within 4 h when cells were exposed to 10 nM of P4. The
prolonged exposure to P4 did not alter the WISP-2 mRNA
level in MCF-7 breast cancer cells, as previously reported
[41]. Moreover, studies indicate that progesterone act
through a PR-dependent mechanism to increase WISP-2
mRNA expression.
When breast tumor cells were exposed concurrently to
estrogen and progesterone, the antagonistic action of
progesterone was apparent. These data strongly suggest
that WISP-2 is an estrogen or progesterone- induced early
response gene and may participate in the cascade of events
underlying the progesterone regulation of estradiol action in
breast cancer cells. The mechanisms of interactions are still
to be determined.
Role of WISP-2 Expression in Cellular Proliferation
Data presented in this report and previous studies
[21,22,33,34] have shown that the transcriptional and
translational activation of WISP-2 gene is a characteristic
of breast cancer cells and suggesting that WISP-2 expres-
sion may be critical for the growth and survivability of breast
tumor cells. To test the hypothesis, the impact of WISP-2
antisense oligos on serum- induced breast tumor derived
MCF-7 cell proliferation was determined. Antisense ap-
proaches have been used to inhibit the function of various
genes by blocking the information conveyed from DNA to
protein through RNA by binding a small complementary
nucleotide sequence to the target (see the review) [42]. Our
results indicate that the suppression of endogenous serum-
induced WISP-2 synthesis by antisense oligos (comple-
mentary to WISP-2 cDNA, i.e., mRNA, at the coding region)
inhibited radioactive thymidine or BrdU incorporation into
the MCF-7 cells exposed to serum. In contrast, incorporation
of radioactive thymidine or BrdU into normal breast epithe-
lial cells was unaltered when WISP-2 antisense oligo-
nucleotides were incorporated into these cells. Therefore, it
appears thatWISP-2 signaling is closely correlated with the
serum (mitogen)- induced proliferation in MCF-7 breast
tumor cell line, and indicates a role for WISP-2 in tumor cell
proliferation. Moreover, these novel findings appear to
indicate that WISP-2 is not functioning as a tumor sup-
pressor gene in breast cancer cells, although WISP-2 is
homologous to a recently identified tumor suppressor gene,
rCop-1 [43,44].
Conclusions
The findings presented in this study lead to the conclusion
that WISP-2, a member of CCN family of growth factor, is
overexpressed in human breast tumor samples and exhibits
a close association with ER positivity. Moreover, in vitro
studies demonstrated that the WISP-2 gene is a target of
both estrogen and progesterone and mediated through
estrogen and progesterone receptors. The action of proges-
terone was biphasic. Progesterone alone transiently induced
WISP-2 expression in MCF-7 cells, but in the presence of
estrogen, it exhibits anti–estrogenic effects and inhibited
estrogen- induced WISP-2 mRNA expression. Moreover,
WISP-2 protein content and mitogen- induced MCF-7 cell
proliferation were reduced by WISP-2 antisense oligos
pretreatment, suggesting a major role for WISP-2 signaling
in tumor cell proliferation.
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